Is meropenem MIC increase against KPC-producing Klebsiella pneumoniae correlated with increased resistance rates against other antimicrobials with Gram-negative activity?

Grundmann, 2017, Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study, Lancet Infect Dis, 17, 153, 10.1016/S1473-3099(16)30257-2 Hsu, 2014, Treatment of multidrug-resistant Gram-negative infections in children, Clin Infect Dis, 58, 1439, 10.1093/cid/ciu069 Tumbarello, 2012, Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy, Clin Infect Dis, 55, 943, 10.1093/cid/cis588 Pea, 2017, Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?, Int J Antimicrob Agents, 49, 255, 10.1016/j.ijantimicag.2016.10.018 Cojutti, 2017, Population pharmacokinetics of high-dose continuous-infusion meropenem and considerations for use in the treatment of infections due to KPC-producing Klebsiella pneumoniae, Antimicrob Agents Chemother, 61, 10.1128/AAC.00794-17 Cohen Stuart, 2010, Guideline for phenotypic screening and confirmation of carbapenemases in Enterobacteriaceae, Int J Antimicrob Agents, 36, 205, 10.1016/j.ijantimicag.2010.05.014 Kahlmeter, 2017, EUCAST proposes to change the definition and usefulness of the susceptibility category ‘intermediate’, Clin Microbiol Infect, 23, 894, 10.1016/j.cmi.2017.08.015 Cohen, 2013, Confronting the threat of multidrug-resistant Gram-negative bacteria in critically ill patients, J Antimicrob Chemother, 68, 490, 10.1093/jac/dks460 Bassetti, 2018, Management of KPC-producing Klebsiella pneumoniae infections, Clin Microbiol Infect, 24, 133, 10.1016/j.cmi.2017.08.030 Kaiser, 2013, Trends in Klebsiella pneumoniae carbapenemase-positive K. pneumoniae in US hospitals: report from the 2007–2009 SENTRY Antimicrobial Surveillance Program, Diagn Microbiol Infect Dis, 76, 356, 10.1016/j.diagmicrobio.2013.03.032 Karaiskos, 2017, Combination therapy for extensively-drug resistant Gram-negative bacteria, Expert Rev Anti Infect Ther, 15, 1123, 10.1080/14787210.2017.1410434 Ramirez, 2010, Aminoglycoside modifying enzymes, Drug Resist Updat, 13, 151, 10.1016/j.drup.2010.08.003 Warburg, 2012, A carbapenem-resistant Klebsiella pneumoniae epidemic clone in Jerusalem: sequence type 512 carrying a plasmid encoding aac(6′)-Ib, J Antimicrob Chemother, 67, 898, 10.1093/jac/dkr552 Livermore, 2011, Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates, J Antimicrob Chemother, 66, 48, 10.1093/jac/dkq408 Tam, 2017, Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria, J Antimicrob Chemother, 72, 1421, 10.1093/jac/dkx001